Analysis-Innovent’s weight-loss drug highlights China challenge for Novo, Lilly
By Andrew Silver SHANGHAI (Reuters) -Innovent Biologics’ newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals as it pursues a marketing strategy that is gaining traction. Xinermei, launched in July, is the third once-weekly injectable GLP-1 weight management therapy available in China after Novo…